<DOC>
	<DOCNO>NCT01709318</DOCNO>
	<brief_summary>The study design evaluate ovulation inhibition , vaginal bleeding , pharmacokinetics associate three different dos two next generation vaginal ring ( NGRs ) , identify least one whose control menstrual cycle inferior NuvaRing® .</brief_summary>
	<brief_title>A Dose-Finding Study Evaluate Ovarian Function Vaginal Bleeding Next Generation Rings ( P06109/MK-8175A/MK-8342B-012 )</brief_title>
	<detailed_description />
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Body mass index ( BMI ) ≥18 ≤35 Regular cycle 24 35 day length , intraindividual variation ±3 day permit within range Good physical mental health Diabetes mellitus vascular involvement Presence severe multiple risk factor ( ) venous arterial thrombosis Severe dyslipoproteinemia Severe hypertension Presence history pancreatitis associate severe hypertriglyceridaemia Presence history severe hepatic disease Undiagnosed vaginal bleeding Known suspect pregnancy Participation another investigational drug study within 30 day prior screen visit History malignancy ≤5 year , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer Documented abnormal cervical smear result 6 month prior screen visit Sterilization use use fallopian tube occlusion device ( e.g. , Essure method ) Sex hormone therapy within 2 month prior screen visit purpose contraception , injectable hormonal contraception within 6 month prior screen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>